nctId: NCT06340906 id: 4573 id: UCI 23-29 type: OTHER domain: CFCCC briefTitle: Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-11-15 date: 2026-01-30 date: 2024-04-02 date: 2024-04-03 name: University of California, Irvine class: OTHER briefSummary: The investigators are conducting this research study is to evaluate the feasibility (recruitment, compliance, safety, and acceptance) of using electroacupuncture (EA) to manage complex symptoms such as pain, nausea/vomiting, diarrhea, and insomnia in patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Additionally, the investigators are aiming to determine the effectiveness of EA in reducing these symptoms, and to examine how EA impacts important biomarkers, or proteins in the blood, that can be used as indicators or signs of these symptoms. conditions: Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a single-arm, prospective pilot/feasibility study. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 20 type: ESTIMATED name: Electroacupuncture measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Number of Patients Recruited measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Patient Recruitment Rate measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Reasons for Abstaining from Participation measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Recruitment Duration measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Number of Completed Electroacupuncture Sessions measure: Feasibility in utilizing an EA for patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - Proportion of Completed Electroacupuncture Sessions measure: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - EORTC QLQ-C30 measure: Efficacy of EA in managing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - EORTC QLQ-C30 measure: Efficacy of EA in managing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - FACT-Cog version 3 measure: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Symptoms - FACT-Cog version 3 measure: Biomarkers - Plasma (pg/mL) measure: Vital Signs - Blood Pressure (mmHg) measure: Vital Signs - Heart Rate (bpm) measure: Vital Signs - Body Temperature (C) measure: Vital Signs - Respiration Rate (breaths/minute) measure: Vital Signs - Oxygen Saturation Rate (%) measure: Height (feet and inches) measure: Weight (kg) measure: Incidence of Treatment-Emergent Adverse Events - Safety Monitoring measure: Biomarkers - Plasma BDNF (pg/ml) measure: Biomarkers - Plasma cytokines (IL-1β, IL-4, IL-6, IL-8, IL-10, TNF-alpha, pg/mL) measure: Mitochondrial DNA content sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UCI Health Susan Samueli Integrative Health Institute city: Irvine state: California zip: 92697 country: United States name: Matthew Heshmatipour, BSc role: CONTACT email: mheshmat@hs.uci.edu lat: 33.66946 lon: -117.82311 hasResults: False